✦ LIBER ✦

Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz

✍ Scribed by Marco Siccardi, Adeniyi Olagunju, Kay Seden, Farid Ebrahimjee…

Book ID: 120802999
Publisher: Springer (Biomed Central Ltd.)
Year: 2013
Tongue: English
Weight: 257 KB
Volume: 1
Category: Article
ISSN: 2193-9616
DOI: 10.1186/2193-9616-1-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erratum to: Prediction of Drug–Drug Inte

Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

✍ Marco Siccardi, Catia Marzolini, Kay Seden, Lisa Almond… 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 180 KB

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4